logo-loader
Callitas Health Inc.

M Pharmaceutical boss looking forward to a great 2017 and 2018

Gary Thompson is at the helm of drug company M Pharmaceutical, which he describes as a "small company with big ideas".
Talking to Proactive, he said that when finished soon with its acquisition of Cincinnati-based 40 J’s, it will have a current revenue stream from about seven different products, which are FDA cleared.
There are also excitingly two products going through FDA process now - a side-effect-free version of the best-selling slimming product orlistat and a female sexual dysfunction (FSD) remedy.
"I'm looking forward to a great 2017 and 2018," said Thompson.

Quick facts: Callitas Health Inc.

Price: $0.11

Market: CSE
Market Cap: $3.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc. named herein, including the promotion by the Company of Callitas Health Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Callitas Therapeutics signs LOI with Simply Wholeistic, updates on THC & CBD...

Callitas Therapeutics (CSE:LILY) (OTCQB:MPHMF) Vice President of Sales & Business Development Joshua Maurice tells Proactive Investors the pharma company has signed a letter of intent with Simply Wholeistic to manufacture  its CannaStrip products in the U.S. Maurice added that as...

on 25/4/19

2 min read